Pfizer (PFE) announced that the European Commission has issued a decision amending the marketing authorization for Abrysvo, the company’s bivalent respiratory syncytial virus prefusion F vaccine, to extend the indication to include prevention of lower respiratory tract disease caused by RSV in individuals 18 through 59 years of age. This expands the previous authorization for individuals aged 60 and older, and Abrysvo now offers in the EU the broadest RSV vaccine indication, which includes: active immunization of individuals 18 years of age and older for the prevention of LRTD caused by RSV; passive protection against lower respiratory tract disease caused by RSV in infants from birth through six months of age following maternal immunization during pregnancy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer’s Strategic Adaptation to Part D Redesign Drives Buy Rating
- Pfizer’s Strong Financial Performance and Strategic Developments Drive Buy Rating
- Hold Rating Maintained for Pfizer Amid Revenue Concerns and Limited Catalysts
- Senator Slams Pfizer (PFE) for “Biggest Tax-Dodging Scheme in Pharma History”
- Healthcare Stocks Sicken as RFK JR Cuts Thousands of Jobs at Health Department